HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 4 April 2011

Gene expression profiling for NICE

After the successful piloting of the Diagnostic Assessment Programme (DAP), NICE is pushing forward with the first wave of topics.  HEDS has been allocated gene expression profiling (GEP) to guide selection of chemotherapy regimes in breast cancer management.  GEP tests, such as oncotype, allow additional information to be gained relating to the chemosensitivity of the tumour and/or recurrence risk.  This then allows treatments to be better targeted, and in theory, improve prognosis.  Whether use of these tests is cost-effective, is an open question.

HEDS’ work will include a full systematic review of the tests and the development of a de novo cost-effectiveness model.  The work is being undertaken by Sue Ward, Rachid Rafia, Alison Scope and Abdullah Pandor.